Heart failure with preserved ejection fraction (HFpEF) is underdiagnosed in patients with severe secondary tricuspid regurgitation (STR) of undefined etiology (isolated STR), according to a study ...

Objective: To provide an overview of heart failure with preserved ejection fraction (HFPEF), as well as its pathophysiology, diagnosis, and clinical evidence regarding its pharmacologic management.

An international team of researchers has discovered a natural mechanism that protects the heart from heart failure with preserved ejection fraction (HFpEF), a serious condition in need of effective ...

Duke-NUS scientists and their collaborators have discovered a potential new treatment for heart failure with preserved ejection fraction (HFpEF), a type of heart disease that is notoriously difficult ...

New imaging tools, exercise testing, and phenotype-based therapy are reshaping how clinicians diagnose and treat HFpEF.

Right ventricular dysfunction (RVD) is prevalent in 41.7% of patients with heart failure with preserved ejection fraction ...

Heart failure with preserved ejection fraction (HFpEF) appears to develop as a result of changes in the biology of a person's internal fat tissue, according to the Adipokine Hypothesis, a new way of ...

About The Study: In patients with cardiometabolic heart failure with preserved ejection fraction, semaglutide and tirzepatide showed more than 40% risk reduction for the composite of hospitalization ...